Richard Mangano - Relmada Therapeutics Chief Scientific Officer
| RLMD Stock | USD 3.29 0.27 8.94% |
Executive
Dr. Richard M. Mangano, Ph.D, was our Chief Scientific Officer since October 2015. Dr. Mangano joined the Company in May 2014 as our Senior Vice President of Clinical Development. Dr. Mangano has extensive experience leading global RD programs in both large and small pharmaceutical companies including positions in discovery and clinical research at HoffmannLa Roche, Lederle Laboratories, Wyeth Research and Adolor Corporationrationration. He served as acting Therapeutic Area Director for Neuroscience at Wyeth before joining Adolor where he was Vice President of Clinical Research and Development from August 2008 to June 2013. Dr. Manganos expertise includes multiple INDCTC submissions and NDAMAA approvals in psychiatry, neurology and gastrointestinal therapeutic areas. Since June 2011, Dr. Mangano was an adjunct professor in the Department of Pharmacology and Physiology at the Drexel University School of Medicine. He lectures in the Drug Discovery and Development Program and in the Psychiatry Departments Resident Training Program. He has authored 30 peer reviewed publications and over 120 abstracts and presentations since 2015.
| Age | 74 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134 |
| Phone | 786-629-1376 |
| Web | https://www.relmada.com |
Relmada Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5913) % which means that it has lost $0.5913 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0041) %, meaning that it created substantial loss on money invested by shareholders. Relmada Therapeutics' management efficiency ratios could be used to measure how well Relmada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -1.06. In addition to that, Return On Capital Employed is expected to decline to -1.28. At present, Relmada Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.52, whereas Total Current Assets are forecasted to decline to about 60.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Christopher Dinsmore | Third Harmonic Bio | 57 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| John JD | Edgewise Therapeutics | 60 | |
| Douglas Kling | NewAmsterdam Pharma | 51 | |
| Conor CPA | Shattuck Labs | N/A | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Steven JD | Cytokinetics | 65 | |
| Debra Feldman | Dyne Therapeutics | 53 | |
| John Moore | Edgewise Therapeutics | 60 | |
| Jan Smith | Revolution Medicines | N/A | |
| Sheng Cui | NewAmsterdam Pharma | N/A | |
| Ommer Chohan | Third Harmonic Bio | N/A | |
| George Fromm | Shattuck Labs | N/A | |
| Michael Naso | Century Therapeutics | N/A | |
| William MD | RAPT Therapeutics | 58 | |
| Moses Makunje | Nuvation Bio | 45 | |
| Chad Cowan | Century Therapeutics | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Richard MBA | Dyne Therapeutics | 38 | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.59 |
Relmada Therapeutics Leadership Team
Elected by the shareholders, the Relmada Therapeutics' board of directors comprises two types of representatives: Relmada Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Relmada. The board's role is to monitor Relmada Therapeutics' management team and ensure that shareholders' interests are well served. Relmada Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Relmada Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Hixon, Head Commercial | ||
| Marco MD, Chief Officer | ||
| Andrew Cutler, Senior Advisor | ||
| Richard Mangano, Chief Scientific Officer | ||
| MBA MBA, CEO Director | ||
| PharmD MBA, CEO Director | ||
| RPh MBA, Chief Officer | ||
| Gina DiGuglielmo, VP Operations | ||
| Paolo MD, Chief Officer |
Relmada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Relmada Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 37.01 M | ||||
| Shares Outstanding | 30.17 M | ||||
| Shares Owned By Insiders | 8.04 % | ||||
| Shares Owned By Institutions | 46.06 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Earning | (1.27) X | ||||
| Price To Book | 1.91 X | ||||
| EBITDA | 4.91 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.59) | Return On Equity (1.00) |
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.